Ovarian microcystic stromal tumour

From Libre Pathology
Revision as of 14:23, 16 October 2019 by Michael (talk | contribs) (→‎General)
Jump to navigation Jump to search

Ovarian microcystic stromal tumour (abbreviated MST), also microcystic stromal tumour of the ovary, is a rare ovarian tumour.

Ovarian microcystic stromal tumour
Diagnosis in short

LM microscopic cysts alternating with solid cellular regions, hyalinized fibrous stroma
LM DDx other sex cord stromal tumours
IHC CD10 +ve (cytoplasmic), beta-catenin (nuclear) +ve, WT-1 +ve, cyclin D1 +ve, inhibin -ve, calretinin -ve, ER-, PR-
Site ovary, testis

Prevalence rare, evolving entity
Prognosis unknown
Clin. DDx other ovarian tumours, testicular tumours
Treatment excision

General

Microscopic

Features:[3]

  • Microcysts alternating with solid cellular regions.
  • Hyalinized fibrous stroma.

Images

IHC

Features:[3]

  • CD10 +ve (cytoplasmic).
  • Beta-catenin +ve (nuclear).
  • WT1 +ve.
  • Cyclin D1 +ve.
  • Inhibin -ve.
  • Calretinin -ve.
  • ER -ve.
  • PR -ve.

Molecular

  • CTNNB1 mutation.[4]

References

  1. Zhu, P.; Duan, Y.; Ao, Q.; Wang, G. (Oct 2018). "Microcystic Stromal Tumor of Testicle: First Case Report and Literature Review.". Cancer Res Treat 50 (4): 1452-1457. doi:10.4143/crt.2017.414. PMID 29169232.
  2. Irving, JA.; Lee, CH.; Yip, S.; Oliva, E.; McCluggage, WG.; Young, RH. (Oct 2015). "Microcystic Stromal Tumor: A Distinctive Ovarian Sex Cord-Stromal Neoplasm Characterized by FOXL2, SF-1, WT-1, Cyclin D1, and β-catenin Nuclear Expression and CTNNB1 Mutations.". Am J Surg Pathol 39 (10): 1420-6. doi:10.1097/PAS.0000000000000482. PMID 26200099.
  3. 3.0 3.1 McCluggage, WG.; Chong, AS.; Attygalle, AD.; Clarke, BA.; Chapman, W.; Rivera, B.; Foulkes, WD. (Feb 2019). "Expanding the morphological spectrum of ovarian microcystic stromal tumour.". Histopathology 74 (3): 443-451. doi:10.1111/his.13755. PMID 30325056.
  4. Na, K.; Kim, EK.; Jang, W.; Kim, HS. (Jun 2017). "CTNNB1 Mutations in Ovarian Microcystic Stromal Tumors: Identification of a Novel Deletion Mutation and the Use of Pyrosequencing to Identify Reported Point Mutation.". Anticancer Res 37 (6): 3249-3258. doi:10.21873/anticanres.11688. PMID 28551672.